8-K: RenovoRx Appoints Dr. Agah Executive Chairman, Boosts Pay

RenovoRx, Inc. formally appointed Dr. Ramtin Agah as Executive Chairman, effective February 27, 2026, alongside his Chief Medical Officer role, with a new compensation package.

Summary

• RenovoRx, Inc. appointed Dr. Ramtin Agah to the newly created position of Executive Chairman, effective February 27, 2026.
• Dr. Agah will continue in his role as Chief Medical Officer and Chairman of the Board.
• His new compensation package includes an annualized base salary of $450,000, based on a minimum of 30 hours worked per week, effective January 1, 2026.
• Dr. Agah is eligible for an annual discretionary bonus of up to 40% of his annualized base salary, dependent on company and individual performance, with the first bonus payable in 2027 for 2026 performance.
• He will also be eligible to receive annual grants of options to purchase common stock and other compensatory awards like restricted stock units under the company's 2021 Omnibus Equity Incentive Plan.
• Dr. Agah's employment is at-will, meaning either party can terminate employment at any time for any reason.
• The new offer letter amends, restates, and replaces a previous Consulting Agreement dated January 1, 2018, but acknowledges that an Amended and Restated Change in Control and Severance Agreement dated November 10, 2025, remains in full force and effect.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting stability and an expanded role for a key executive. While it increases compensation costs, it solidifies leadership in critical areas, which is beneficial for long-term strategic execution.

Positives

• Retention of a key executive, Dr. Ramtin Agah, in an expanded leadership role as both Chief Medical Officer and Executive Chairman.
• Formalization of a clear leadership structure with Dr. Agah coordinating with the CEO and reporting to the Board of Directors.
• The compensation package, including base salary, performance-based bonus potential, and equity awards, is designed to align executive incentives with company performance.

Negatives

• Increased executive compensation represents a higher fixed cost for the company.
• The discretionary nature of the annual bonus (up to 40%) introduces variability in executive compensation and depends solely on company discretion and performance.

Risks

• The company's reliance on a single key executive (Dr. Agah) for dual critical roles (Chief Medical Officer and Executive Chairman) could pose a risk if he were to depart.
• The at-will employment status means Dr. Agah or the company can terminate the employment relationship at any time, which could introduce leadership instability.
• The performance-based bonus is subject to company and individual performance, which may not always be met, potentially impacting executive motivation or retention.

Future Outlook

Dr. Agah will be eligible to receive annual grants of options to purchase shares of the company's common stock, as well as other compensatory awards such as restricted stock units, as determined by the Compensation Committee of the Board.

Management Comments

• Shaun R. Bagai, Chief Executive Officer, expressed the company's anticipation of continuing work with Dr. Agah in his new role.

Industry Context

StockSavvy.ai notes that retaining experienced medical leadership is crucial for biotech and medical device companies like RenovoRx, especially when navigating clinical development, regulatory pathways, and strategic growth. The dual role of Chief Medical Officer and Executive Chairman suggests a strong emphasis on integrating medical strategy directly with corporate governance and overall business direction, which can be a competitive advantage in the highly specialized healthcare sector.

Comparison to Industry Standards

• StockSavvy.ai observes that executive compensation packages in the biotech and medical device sectors often include a significant equity component and performance-based bonuses, aligning executive incentives with company performance and shareholder value.
• Dr. Agah's base salary of $450,000 and bonus potential of up to 40% appear competitive for a dual role of this magnitude in a development-stage company, particularly given the critical medical and strategic responsibilities. However, specific comparisons would require detailed peer group analysis of companies with similar market capitalization, stage of development, and executive roles.

Management Changes

Corporate Governance

Related Party Transactions

• The Agah Offer Letter, dated March 24, 2026, amends, restates, and replaces a Consulting Agreement dated January 1, 2018, between Dr. Agah and the Company.
• The Amended and Restated Change in Control and Severance Agreement, dated November 10, 2025, between the Company and Dr. Agah, remains in full force and effect.

Stakeholder Impact

• Shareholders: Impacted by increased executive compensation and the potential for enhanced strategic leadership and stability through the expanded role of a key executive.
• Employees: General employee benefits are summarized in Exhibit B, indicating standard offerings, though the filing primarily focuses on executive compensation.
• Management: The CEO will coordinate with the Executive Chairman, establishing a clear reporting and collaborative structure for senior leadership.

Next Steps

• Dr. Agah will perform management-related duties in coordination with the CEO and report to the Board of Directors.
• The Compensation Committee will determine annual grants of options and other compensatory awards.
• The first annual discretionary bonus for 2026 performance will be payable in 2027.

Key Dates

Recommendation

The filing details a key executive's new compensation and expanded role, which is a positive for leadership stability and strategic alignment. However, it does not contain new financial performance data, significant operational shifts, or material clinical trial updates that would warrant a change from a 'hold' position. Investors should monitor future operational and clinical developments for more impactful investment decisions.

Keywords

RenovoRx, Ramtin Agah, Executive Chairman, Chief Medical Officer, Executive Compensation, Corporate Governance, SEC Filing, Biotech, Medical Device, Leadership Appointment